Patients
liver and kidney damage, traumatic brain injury, epilepsy, coagulation dysfunction, cerebral vascular malformation, gastrointestinal and urinary system bleeding, communication impairments, Acute Ischemic Stroke, aphasia, acute ischemic stroke
HEMORRHAGIC STROKE, EPILEPSY, INTRACRANIAL HEMORRHAGE, HEARING IMPAIRMENT, ACUTE ISCHEMIC STROKE, DISEASES, DRUG ALLERGY
A total of 126 patients diagnosed with acute ischemic stroke and met the inclusion and exclusion criteria in our hospital were selected as the test subjects. The patients were randomly divided into the control group and the predictive nursing intervention group by the random number table method, with 63 cases in each group. Briefly we used a special shaker to automatically roll out a number one by one to make a table for future reference. The chance of any number in this list is equal. All participants signed written informed consent. The study was approved by the ethics committee of Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine.Inclusion criteria: (1) those who met the diagnostic criteria in “China Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2018”; (2) CT and MRI examinations of the brain meet the diagnostic criteria for acute ischemic stroke; (3) first onset, acute onset, onset time ≤ 4.5 h; (4) those who met the indications for thrombolytic therapy; (5) expected survival time ≥ 3 months; (6) no coagulation dysfunction; no history of drug allergy; no severe liver and kidney damage; no aphasia, hearing impairment, etc.; (7) who were able to read and understand the informed consent form.Exclusion criteria: (1) those who have diseases such as abnormal immune system and coagulation dysfunction; (2) those who have traumatic brain injury, hemorrhagic stroke, cerebral vascular malformation, epilepsy; (3) those who have history of intracranial hemorrhage; (4) those who have experienced gastrointestinal and urinary system bleeding in the past 3 weeks; (5) those who have undergone arterial puncture in the past 7 days; (6) those who have received anticoagulant therapy; (7) those who have previous cognitive, mental, and communication impairments and cannot cooperate with this researcher.Patients in both control group and intervention group received thrombolytic therapy with alteplase at a dose of 0.9 mg/kg (maximum dose 90 mg). Ten percent of the total dose of the drug was injected intravenously within 1 min, and the remaining 90% was intravenously pumped at a uniform rate within 1 h. The patient's vital signs need to be closely monitored and the patient's blood pressure should be monitored every 15 min at 2 h after thrombolytic therapy, t. Head CT was performed to rule out intracranial hemorrhage, and aspirin 200 mg/day was administered orally at 24 h after thrombolysis. If the patient has intracranial hemorrhage, various conventional treatments such as anti‐arteriosclerosis should be carried out in time and attention should be paid to improving cerebral circulation.